Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387537 | 0.87 | NLRP3 (0.54) | NLRP3ALDH1A1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL4855183 | 0.83 | ESR1 (0.51) | NLRP3ALDH1A1CA12CA1CA9 | |
| SCHEMBL2847349 | 0.82 | AAK1 (0.43) | NLRP3ALDH1A1CA12CA1CA9 | |
| SCHEMBL8649013 | 0.82 | NLRP3 (0.46) | NLRP3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1549923 | 0.80 | NLRP3 (0.48) | NLRP3ALDH1A1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL4856473 | 0.80 | EPHX2 (0.54) | ALDH1A1PPARGKDM4ECYP1A2IDH1 | |
| SCHEMBL7390785 | 0.79 | NLRP3 (0.46) | NLRP3ALDH1A1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL8194998 | 0.78 | CD69 (0.46) | NLRP3ALDH1A1CA12CA9KDM4E | |
| SCHEMBL7475639 | 0.78 | SMN1; SMN2 (0.56) | ALDH1A1PPARGCYP1A2CYP2C19IDH1 | |
| SCHEMBL16302366 | 0.77 | CA12 (0.51) | ALDH1A1CA12CA1CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345067-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | PPARA, PPARD, PPARG | NLRP3 4061/4885ALDH1A1 464/4885CA12 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.